Table 1 Univariate analysis of patients’ baseline characteristics and treatment factors on survival
Characteristics | Number of patients (%) | p value |
|---|---|---|
Sex | 0.070 | |
Male | 56 (54.9%) | |
Female | 46 (45.1%) | |
Age (y) | 0.008 | |
< 60 | 45 (44.1%) | |
≥ 60 | 57 (55.9%) | |
Diagnosis | 0.503 | |
iCCA | 33 (32.4%) | |
GBC | 14 (13.7%) | |
pCCA | 55 (53.9%) | |
Degree of differentiation | 0.078 | |
High differentiation | 2 (2%) | |
Moderate differentiation | 19 (18.6%) | |
Poor differentiation | 28 (27.5%) | |
Unknown | 53 (52%) | |
Previous treatment | 0.447 | |
Yes | 25 (24.5%) | |
No | 77 (75.5%) | |
Hepatitis | 0.345 | |
No | 53 (52%) | |
Hepatitis B | 49 (48%) | |
Hepatitis C | 0 (0) | |
Child–Pugh classification | 0.323 | |
A | 52 (51%) | |
B | 50 (49%) | |
ECOG PS | 0.013 | |
0 | 64 (62.7%) | |
1 | 38 (37.3%) | |
Jaundice | 0.205 | |
Yes | 71 (69.6%) | |
No | 31 (30.4%) | |
Extent of disease | 0.081 | |
NxM0 + N0M0 | 41 (40.2%) | |
N1M0 | 53 (52%) | |
N2M0 + any M1 | 8 (7.8%) | |
SER0 | < 0.001 | |
< 1.04 | 49 (48%) | |
≥ 1.04 | 53 (52%) | |
CEA level | < 0.001 | |
< 10 U/mL | 74 (72.5%) | |
≥ 10 U/mL | 25 (24.5%) | |
Unknown | 3 (2.9%) | |
CA 19-9 level | 0.001 | |
< 200U/mL | 31 (30.4%) | |
≥ 200U/mL | 67 (65.7%) | |
Unknown | 4 (3.9%) | |
Treatment cycle | 0.002 | |
2–4 cycles | 54 (52.9%) | |
5–6 cycles | 48 (47.1%) | |
ΔSER | 0.031 | |
< 0 | 36 (35.3%) | |
> 0 | 66 (64.7%) | |
Subsequent treatment | 0.173 | |
Yes | 63 (61.8%) | |
No | 39 (38.2%) |